Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
peptidase/inflamação
O link é salvo na área de transferência
Página 1 a partir de 16 resultados
Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a U.S. National Stage of International Application No. PCT/EP2004/011644, filed Oct. 15, 2004, which claims priority of German Patent Application No. 103 48 044.7, filed Oct. 15, 2003.
The present invention relates to novel
Dual-use peptidase inhibitors as prodrugs for a therapy of inflammatory and other diseases
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Stage application of International Application No. PCT/EP2006/010818, filed on Nov. 10, 2006, which claims priority of German application number 10 2005 054 700.1, filed on Nov. 16, 2005, both of which are incorporated herein by
Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to new and improved inhibitors of Dipeptidyl-Peptidase-IV (DPP-IV) with beta blocker activity, and new and improved treatment methods and related uses. The inhibitors according to the invention are useful for
Use of Aspergillus niger aspergilloglutamic peptidase to improve animal performance
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
This application is the U.S. national phase of International Application No. PCT/EP2014/077353 filed 11 Dec. 2014 which designated the U.S. and claims priority to EP 13196583.2 filed 11 Dec. 2013, the entire contents of each of which are hereby incorporated by reference.
BRIEF DESCRIPTION OF THE
Dipeptidyl peptidase IV inhibitors
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
FIELD
Described are compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof.
##STR00002##
Described herein is also a
Effectors of dipeptidyl peptidase IV for topical use
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to new effectors of dipeptidyl peptidase IV (DP IV) and methods of treatment comprising the topical application thereof. These effectors can be used for targeted influencing of locally limited pathophysiological and
Effectors of dipeptidyl peptidase IV for topical use
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to new effectors of dipeptidyl peptidase IV (DP IV) and methods of treatment comprising the topical application thereof. These effectors can be used for targeted influencing of locally limited pathophysiological and
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
FIELD OF THE INVENTION
The present invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (hereinafter "DPP-IV"), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with
OF4949
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The present invention relates to novel compounds including a substance named OF4949, to processes for the production thereof, to pharmaceutical compositions containing such compounds as the active agent and to methods of treatment utilizing said compounds.
More particular, the compounds of the
Peptide-lipid conjugates
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
FIELD OF THE INVENTION
Peptide-lipid conjugates are incorporated into liposomes so as to localize delivery of the liposomes' contents to the vicinity of target cells.
BACKGROUND OF THE INVENTION
Liposomes have been widely used as carriers to deliver a variety of therapeutic and diagnostic agents
Liposomal peptide-lipid conjugates and delivery using same
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
FIELD OF THE INVENTION
Peptide-lipid conjugates are incorporated into liposomes so as to localize delivery of the liposomes' contents to the vicinity of target cells.
BACKGROUND OF THE INVENTION
Liposomes have been widely used as carriers to deliver a variety of therapeutic and diagnostic agents
Peptide-lipid conjugates, liposomes and lipsomal drug delivery
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
FIELD OF THE INVENTION
Peptide-lipid conjugates are incorporated into liposomes so as to localize delivery of the liposomes' contents to the vicinity of target cells.
BACKGROUND OF THE INVENTION
Liposomes have been widely used as carriers to deliver a variety of therapeutic and diagnostic agents
Combinations of enzyme inhibitor-containing preparations and the use thereof
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The present invention describes the combined inhibition of the activity of the enzymes Aminopeptidase N (APN; E.C. 3.4.11.2.; CD13), Dipeptidyl peptidase IV (DP IV; E.C. 3.4.14.5; CD26), Prolyl oligopeptidase (POP; Prolyl endopeptidase; PEP; E.C. 3.4.21.26), the membrane-adherent Aminopeptidase P
Drug containing angiotensin convertase
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
This application is a U.S. national stage of International Application No. PCT/JP2003/013851 filed Oct. 29, 2003.
TECHNICAL FIELD
This application relates to the invention of angiotensin-converting enzyme containing medicine. In detail, the invention of this application relates to a medicine that is
Labelled glutamine and lysine analogues
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The present invention relates to a class of compounds useful in the diagnosis of sites of venous and arterial thrombosis, embolism or infection, pharmaceutical formulations containing them, their use in the diagnosis of disease and methods for their preparation.
Prior approaches to thrombus imaging
O mais completo banco de dados de ervas medicinais apoiado pela ciência
- Funciona em 55 idiomas
- Curas herbais apoiadas pela ciência
- Reconhecimento de ervas por imagem
- Mapa GPS interativo - marcar ervas no local (em breve)
- Leia publicações científicas relacionadas à sua pesquisa
- Pesquise ervas medicinais por seus efeitos
- Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes
Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas
